JP2023526218A5 - - Google Patents

Info

Publication number
JP2023526218A5
JP2023526218A5 JP2022568638A JP2022568638A JP2023526218A5 JP 2023526218 A5 JP2023526218 A5 JP 2023526218A5 JP 2022568638 A JP2022568638 A JP 2022568638A JP 2022568638 A JP2022568638 A JP 2022568638A JP 2023526218 A5 JP2023526218 A5 JP 2023526218A5
Authority
JP
Japan
Prior art keywords
domain
fusion protein
protein according
igg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568638A
Other languages
English (en)
Japanese (ja)
Other versions
JP7834347B2 (ja
JP2023526218A (ja
Filing date
Publication date
Priority claimed from CN202010393721.9A external-priority patent/CN113637084B/zh
Application filed filed Critical
Publication of JP2023526218A publication Critical patent/JP2023526218A/ja
Publication of JP2023526218A5 publication Critical patent/JP2023526218A5/ja
Priority to JP2025209848A priority Critical patent/JP2026035742A/ja
Application granted granted Critical
Publication of JP7834347B2 publication Critical patent/JP7834347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568638A 2020-05-11 2021-05-10 生体高分子標的特異的補体阻害剤及びその製造方法と応用 Active JP7834347B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025209848A JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010393721.9A CN113637084B (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN202010393721.9 2020-05-11
PCT/CN2021/092861 WO2021228052A1 (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025209848A Division JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Publications (3)

Publication Number Publication Date
JP2023526218A JP2023526218A (ja) 2023-06-21
JP2023526218A5 true JP2023526218A5 (enExample) 2025-06-17
JP7834347B2 JP7834347B2 (ja) 2026-03-24

Family

ID=78415417

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568638A Active JP7834347B2 (ja) 2020-05-11 2021-05-10 生体高分子標的特異的補体阻害剤及びその製造方法と応用
JP2025209848A Pending JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025209848A Pending JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Country Status (6)

Country Link
US (1) US20230348554A1 (enExample)
EP (1) EP4151659A4 (enExample)
JP (2) JP7834347B2 (enExample)
CN (2) CN113637084B (enExample)
CA (1) CA3178088A1 (enExample)
WO (1) WO2021228052A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920849A (zh) * 2022-03-09 2022-08-19 安徽省立医院(中国科学技术大学附属第一医院) 一种靶向补体免疫抑制蛋白及其构建方法及应用
TW202523706A (zh) * 2023-11-13 2025-06-16 大陸商瀋陽三生製藥有限責任公司 一種靶向C3b的雙功能融合蛋白及其製備方法與用途
CN121159642B (zh) * 2025-11-20 2026-04-03 山东第二医科大学 补体c9迷你结合蛋白或其突变体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
JP7793287B2 (ja) * 2017-10-18 2026-01-05 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
CA3100071A1 (en) * 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
US20220009979A1 (en) * 2018-08-22 2022-01-13 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Similar Documents

Publication Publication Date Title
KR950014915B1 (ko) 탈시알로당단백-포함화합물
CN109641034B (zh) 聚乙二醇化的猪干扰素及其使用方法
JP2023526218A5 (enExample)
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
JP6047495B2 (ja) 持続型インターフェロンアルファ結合体の液状製剤
JP2021512881A5 (enExample)
KR20180100439A (ko) 이중특이적 항체 작제물을 포함하는 약제학적 조성물
JP2017538395A5 (enExample)
JP2016534052A5 (enExample)
CN105848645A (zh) 持续型人生长激素制剂
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
TWI617324B (zh) 高度濃縮之長效人類生長激素共軛物之液體製劑
US11510966B2 (en) Use of IL-22 in treating necrotizing enterocolitis
TW201735940A (zh) 長效人類生長激素共軛物之新穎液體調配物
US20030148265A1 (en) Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein
TW202200193A (zh) 包含il-2蛋白及cd80蛋白的融合蛋白調配物
JP3770624B2 (ja) ウィルス感染・増殖抑制剤
US12485160B2 (en) Stable lyophilized formulation for hybrid Fc fused G-CSF
JP2009511510A (ja) 肝不全の予防・治療用薬品の調製における効果の長いヒト組換え可溶性腫瘍壊死因子α受容体の使用
WO2024059149A2 (en) Immunogenic coronavirus fusion proteins and related methods
EA045982B1 (ru) СТАБИЛЬНЫЙ ЛИОФИЛИЗИРОВАННЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
HK40033832B (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
HK40033832A (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
EA052740B1 (ru) Иммуногенные слитые белки коронавируса и связанные с ними способы